Skip to main content

ESTRATEGIAS FARMACOLOGICAS DE PREVENCION DEL CANCER DE MAMA MEDIANTE MODIFICACION DE LA INVOLUCION POSTLACTANCIA

SAF2017-88854-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The biological age linked to oxidative stress modifies breast cancer aggressiveness

  • Sáez-Freire, María del Mar
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • Gómez-Vecino, Aurora
  • Galvis-Jiménez, Julie Milena
  • Martín-Seisdedos, Carmen
  • Isidoro-García, María
  • Hontecillas-Prieto, Lourdes
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Mao, Jian-Hua
  • Prieto, Carlos
  • Castellanos-Martín, Andrés
  • Kaderali, Lars
  • Pérez-Losada, J.
The incidence of breast cancer increases with age until menopause, and breast cancer is more aggressive in younger women. The existence of epidemiological links between breast cancer and aging indicates that both processes share some common mechanisms of development. Oxidative stress is associated with both cancer susceptibility and aging. Here we observed that ERBB2-positive breast cancer, which developed in genetically heterogeneous ERBB2-positive transgenic mice generated by a backcross, is more aggressive in chronologically younger than in older mice (differentiated by the median survival of the cohort that was 79 weeks), similar to what occurs in humans. In this cohort, we estimated the oxidative biological age using a mathematical model that integrated several subphenotypes directly or indirectly related to oxidative stress. The model selected the serum levels of HDL-cholesterol and magnesium and total AKT1 and glutathione concentrations in the liver. The grade of aging was calculated as the difference between the predicted biological age and the chronological age. This comparison permitted the identification of biologically younger and older mice compared with their chronological age. Interestingly, biologically older mice developed more aggressive breast cancer than the biologically younger mice. Genomic regions on chromosomes 2 and 15 linked to the grade of oxidative aging were identified. The levels of expression of Zbp1 located on chromosome 2, a gene related to necroptosis and inflammation, positively correlated with the grade of aging and tumour aggressiveness. Moreover, the pattern of gene expression of genes linked to the inflammation and the response to infection pathways was enriched in the livers of biologically old mice. This study shows part of the complex interactions between breast cancer and aging., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R and SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), >Proyectos Integrados IBSAL 2015> (IBY15/00003), the Sandra Ibarra Foundation >de Solidaridad Frente al Cáncer> Foundation and >We can be heroes> Foundation. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02-05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Supplementary data for the biological age linked to oxidative stress modifies breast cancer aggressiveness

  • Sáez-Freire, María del Mar
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • Gómez-Vecino, Aurora
  • Galvis-Jiménez, Julie Milena
  • Martín-Seisdedos, Carmen
  • Isidoro-García, María
  • Hontecillas-Prieto, Lourdes
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Mao, Jian-Hua
  • Prieto, Carlos
  • Castellanos-Martín, Andrés
  • Kaderali, Lars
  • Pérez-Losada, J.
The data presented in this article are related to the research paper entitled “The biological age linked to oxidative stress modifies breast cancer aggressiveness” (M.M. Sáez-Freire, A. Blanco-Gómez, S. Castillo-Lluva, A. Gómez-Vecino, J.M. Galvis-Jiménez, C. Martín-Seisdedos, M. Isidoro-García, L. Hontecillas-Prieto, M.B. García-Cenador, F.J. García-Criado, M.C. Patino-Alonso, P. Galindo-Villardón, J.H. Mao, C. Prieto, A. Castellanos-Martín, L. Kaderali, J. Pérez-Losada). The data shown were obtained from a population of transgenic mice, MMTV-Erbb2/Neu, with different susceptibility to breast cancer and a mixed genetic background generated by backcrossing. It was observed that the aggressiveness of breast cancer negatively correlates with age, being lower in chronologically old mice, similar to what occurs in humans. Given that oxidative stress is associated with tumour susceptibility and the degree of aging, the association between the aggressiveness of breast cancer and multiple intermediate phenotypes directly or indirectly related to oxidative stress was studied. Using a mathematical model, we defined biological age and the degree of aging as the difference between biological and chronological ages. As a result, we observed that biologically old mice predominated among those that developed the disease early on, that is, those that were chronologically young. We then identified the specific and common genetic components of Quantitative Trait loci or QTL associated with different evolution of breast cancer, the intermediate phenotypes related to oxidative stress studied, the biological age and the degree of aging. Lastly, we showed that the expression pattern in the livers of biologically old mice were enriched in signalling pathways related to inflammation and response to infections; whereas the biologically young mice exhibited enriched pathways related to mitochondrial activity. For the explanation and discussion of these data refer to the research article cited above., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), >Proyectos Integrados IBSAL 2015> (IBY15/00003), the Sandra Ibarra Foundation>de Solidaridad Frente al Cáncer> Foundation and >We can be heroes> Foundation. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02−05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice.

  • Cañueto, Javier
  • Burguillo, Javier
  • Moyano-Bueno, David
  • Viñolas-Cuadros, Alex
  • Conde-Ferreirós, Alberto
  • Corchete, Luis A.
  • Pérez-Losada, J.
  • Román-Curto, Concépción
  • Román-Curto, Concépción
[Background]: The new eighth edition of the American Joint Committee on Cancer staging system (AJCC-8) incorporates changes regarding cutaneous squamous cell carcinoma (CSCC)., [Objectives]: We aimed to compare the AJCC-8 staging system with the previous seventh edition of the AJCC staging system (AJCC-7) and the Brigham and Women's Hospital (BWH) alternative staging system to identify their usefulness and the utility of their risk factors in defining prognostic groups in CSCC., [Methods]: A series of 186 CSCCs of the head and neck were retrospectively collected. All 3 staging systems were compared from the standpoint of their ability to predict poor prognosis. Binary logistic regression models were built to determine which risk factors were most relevant., [Results]: Poor prognosis was mainly associated with stage T2 of the AJCC-7, with stages T2b/T3 of the BWH system, and with stage T3 of the AJCC-8. The AJCC-8 and the BWH staging systems displayed overlap with each another in predicting poor prognosis, and both were superior to the AJCC-7. The new risk factors incorporated into the AJCC-8 and the poor degree of differentiation were independently associated with poor outcome., Dr Cañueto is partially supported by a grant (GRS 1342/A/16) from the Regional Health Office of Castile and Leon and by the program INT/M/16/17 from the Regional Health Office of Castile and Leon. Dr Pérez-Losada was partially supported by FEDER and the MICINN (grants SAF2014-56989-R and SAF2017-88854-R), the Instituto de Salud Carlos III (PIE14/00066), and the We Can Be Heroes Foundation
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression

  • Blanco-Gómez, Adrián
  • Hontecillas-Prieto, Lourdes
  • Corchado Cobos, Roberto
  • García-Sancha, Natalia
  • Salvador, Nélida
  • Castellanos-Martín, Andrés
  • Sáez-Freire, María del Mar
  • Mendiburu-Eliçabe, Marina
  • Alonso-López, D.
  • Rivas, Javier de las
  • Lorente, Mar
  • García-Casas, Ana
  • Carmen, Sofía del
  • Abad-Hernández, María del Mar
  • Cruz, Juan Jesús
  • Rodríguez-Sánchez, César Augusto
  • Claros-Ampuero, Juncal
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Orimo, Akira
  • Gridley, Thomas
  • Pérez-Losada, J.
  • Castillo, Sonia
SNAI2 overexpression appears to be associated with poor prognosis in breast cancer, yet it remains unclear in which breast cancer subtypes this occurs. Here we show that excess SNAI2 is associated with a poor prognosis of luminal B HER2+/ERBB2+ breast cancers in which SNAI2 expression in the stroma but not the epithelium correlates with tumor proliferation. To determine how stromal SNAI2 might influence HER2+ tumor behavior, Snai2-deficient mice were crossed with a mouse line carrying the ErbB2/Neu protooncogene to generate HER2+/ERBB2+ breast cancer. Tumors generated in this model expressed SNAI2 in the stroma but not the epithelium, allowing for the role of stromal SNAI2 to be studied without interference from the epithelial compartment. The absence of SNAI2 in the stroma of HER2+/ERBB2+ tumors is associated with: (i) lower levels of cyclin D1 (CCND1) and reduced tumor epithelium proliferation; (ii) higher levels of AKT and a lower incidence of metastasis; (iii) lower levels of angiopoietin-2 (ANGPT2), and more necrosis. Together, these results indicate that the loss of SNAI2 in cancer-associated fibroblasts limits the production of some cytokines, which influences AKT/ERK tumor signaling and subsequent proliferative and metastatic capacity of ERBB2+ breast cancer cells. Accordingly, SNAI2 expression in the stroma enhanced the tumorigenicity of luminal B HER2+/ERBB2+ breast cancers. This work emphasizes the importance of stromal SNAI2 in breast cancer progression and patients' prognosis., S. Castillo-Lluva was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness (Ministerio de Economía y Competitividad; MINECO), and the work was supported by a MINECO/FEDER research grant (SAF2015-64499-R; RTI2018-094130-B-100). N. García-Sancha was partially supported by the RTI2018-094130-B-100 budget. J. Pérez-Losada was partially supported by FEDER funds, the Carlos III Health Institute (PIE14/00066), MINECO (SAF2014-56989-R, SAF2017-88854R), Castile and León (CSI234P18), the Sandra Ibarra Foundation for Solidarity against Cancer and the “We can be heroes” Foundation. N. García-Sancha is a recipient of an FPU fellowship (MINECO/FEDER). R. Corchado-Cobos, M.d.M. Sáez-Freire, and A. Blanco-Gómez were funded by fellowships from the Spanish Regional Government of Castile and León. The development of the Snai2 KO mice was supported by NIH grant R01HD034883 (to T. Gridley)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy

  • Xiao, Yi
  • Yin, Chunli
  • Wang, Yuli
  • Lv, Hanlin
  • Wang, Wenqing
  • Huang, Yurong
  • Pérez-Losada, J.
  • Snijders, Antoine M.
  • Mao, Jian-Hua
  • Zhang, Pengju
© 2018 The Authors., Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for non-small-cell lung cancer (NSCLC) with EGFR activating mutations, but inevitably, the clinical efficacy is impeded by the emergence of acquired resistance. The tumor suppressor gene FBXW7 modulates chemosensitivity in various human cancers. However, its role in EGFR-TKI therapy in NSCLC has not been well studied. Here, we demonstrate that the mice with deficient Fbxw7 have greater susceptibility to urethane-induced lung tumor development. Through analysis of The Cancer Genome Atlas data, we show that deletion of FBXW7 occurs in 30.9% of lung adenocarcinomas and 63.5% of lung squamous cell carcinomas, which significantly leads to decrease in FBXW7 mRNA expression. The reduction in FBXW7 mRNA level is associated with poor overall survival in lung cancer patients. FBXW7 knockdown dramatically promotes epithelial–mesenchymal transition, migration, and invasion in NSCLC cells. Moreover, with silenced FBXW7, EGFR-TKI-sensitive cells become resistant to gefitinib, which is reversed by the mammalian target of rapamycin inhibitor, rapamycin. Furthermore, xenograft mouse model studies show that FBXW7 knockdown enhances tumorigenesis and resistance to gefitinib. Combination of gefitinib with rapamycin treatment suppresses tumor formation of gefitinib-resistant (GR) FBXW7-knockdown cells. In conclusion, our findings suggest that loss of FBXW7 promotes NSCLC progression as well as gefitinib resistance and combination of gefitinib and rapamycin may provide an effective therapy for GR NSCLC., This work was supported by National Natural Science Foundation of China (Nos 81672858, 81470127); by the Natural Science Foundation of Shandong province (No. ZR2014HM032) (to PZ), and Lawrence Berkeley National Laboratory Directed Research and Development (LDRD) program funding under contract DE AC02-05CH11231 (to AMS and JHM); and by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), and the Instituto de Salud Carlos III (PIE14/00066) and ‘We can be heroes’ Foundation (to JPL)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pathophysiological integration of metabolic reprogramming in breast cancer

  • Corchado Cobos, Roberto
  • García-Sancha, Natalia
  • Mendiburu-Eliçabe, Marina
  • Gómez-Vecino, Aurora
  • Jiménez-Navas, Alejandro
  • Pérez-Baena, Manuel Jesús
  • Holgado-Madruga, Marina
  • Mao, Jian-Hua
  • Cañueto, Javier
Metabolic changes that facilitate tumor growth are one of the hallmarks of cancer. The triggers of these metabolic changes are located in the tumor parenchymal cells, where oncogenic mutations induce an imperative need to proliferate and cause tumor initiation and progression. Cancer cells undergo significant metabolic reorganization during disease progression that is tailored to their energy demands and fluctuating environmental conditions. Oxidative stress plays an essential role as a trigger under such conditions. These metabolic changes are the consequence of the interaction between tumor cells and stromal myofibroblasts. The metabolic changes in tumor cells include protein anabolism and the synthesis of cell membranes and nucleic acids, which all facilitate cell proliferation. They are linked to catabolism and autophagy in stromal myofibroblasts, causing the release of nutrients for the cells of the tumor parenchyma. Metabolic changes lead to an interstitium deficient in nutrients, such as glucose and amino acids, and acidification by lactic acid. Together with hypoxia, they produce functional changes in other cells of the tumor stroma, such as many immune subpopulations and endothelial cells, which lead to tumor growth. Thus, immune cells favor tissue growth through changes in immunosuppression. This review considers some of the metabolic changes described in breast cancer., J.P.-L.’s laboratory was partially supported by Grant SAF2017-88854R funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”; Grant PID2020- 118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”. The Carlos III Health Institute (PIE14/00066), the Regional Government of Castile and León (CSI234P18 and CSI144P20) and the “We can be heroes” charity. SCLl was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness and was supported by grant RTI2018-094130-B-100 funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”. R.C.-C. and A.J.-N. are funded by fellowships from the Spanish Regional Government of Castile and León. N.G.-S. is a recipient of an FPU fellowship (MINECO/FEDER). M.J.P.-B. is funded by grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039. J.C. is partially supported by grant GRS2139/A/20 (Gerencia Regional de Salud de Castilla y León) and by the Instituto de Salud Carlos III (PI18/00587 and PI21/01207), co-financed by FEDER funds, and by the “Programa de Intensificación” of the ISCIII, grant number INT20/00074.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies

  • García-Sancha, Natalia
  • Corchado Cobos, Roberto
Breast cancer is the most common malignancy among women globally, with incidence rates continuing to rise. A comprehensive understanding of its risk factors and the underlying biological mechanisms that drive tumor initiation is essential for developing effective prevention strategies. This review examines key non-modifiable risk factors, such as genetic predisposition, demographic characteristics, family history, mammographic density, and reproductive milestones, as well as modifiable risk factors like exogenous hormone exposure, obesity, diet, and physical inactivity. Importantly, reproductive history plays a dual role, providing long-term protection while temporarily increasing breast cancer risk shortly after pregnancy. Current chemoprevention strategies primarily depend on selective estrogen receptor modulators (SERMs), including tamoxifen and raloxifene, which have demonstrated efficacy in reducing the incidence of estrogen receptor-positive breast cancer but remain underutilized due to adverse effects. Emerging approaches such as aromatase inhibitors, RANKL inhibitors, progesterone antagonists, PI3K inhibitors, and immunoprevention strategies show promise for expanding preventive options. Understanding the interactions between risk factors, hormonal influences, and tumorigenesis is critical for optimizing breast cancer prevention and advancing safer, more targeted chemopreventive interventions, This work carried out in JPL’s laboratory, was supported by Grant SAF2017-88854R, funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”; Grants PID2020-118527RB-I00 and PDC2021-121735-I00, funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”; Grant PID2023-153081OB-I00, funded by MCIN/AEI/10.13039/501100011039; the Regional Government of Castile and León (CSI144P20); and the “We can be heroes” charity. N.G.-S. was a recipient of an FPU fellowship (MECD-FPU17/00192). R.C.-C. was founded by a fellowship from the Spanish Regional Government of Castile and León., Peer reviewed